Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer

Koichi Takayama, Masayuki Kawasaki, Kiyoshi Ninomiya, Akira Motohiro, Masaki Fujita, Kentaro Watanabe, Akira Kajiki, Fumiyuki Iwami, Naoki Miyazaki, Miiru Izumi, Nobuyuki Hara, Yoichi Nakanishi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2-43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalRespirology
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Tegafur
Uracil
Non-Small Cell Lung Carcinoma
Cisplatin
Survival
Anorexia
Therapeutics
Nausea
Vomiting
Liver Diseases
Diarrhea
Kidney
Safety
Drug Therapy
Liver

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Takayama, K., Kawasaki, M., Ninomiya, K., Motohiro, A., Fujita, M., Watanabe, K., ... Nakanishi, Y. (2008). Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Respirology, 13(1), 103-107. https://doi.org/10.1111/j.1440-1843.2007.01190.x

Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. / Takayama, Koichi; Kawasaki, Masayuki; Ninomiya, Kiyoshi; Motohiro, Akira; Fujita, Masaki; Watanabe, Kentaro; Kajiki, Akira; Iwami, Fumiyuki; Miyazaki, Naoki; Izumi, Miiru; Hara, Nobuyuki; Nakanishi, Yoichi.

In: Respirology, Vol. 13, No. 1, 01.01.2008, p. 103-107.

Research output: Contribution to journalArticle

Takayama, K, Kawasaki, M, Ninomiya, K, Motohiro, A, Fujita, M, Watanabe, K, Kajiki, A, Iwami, F, Miyazaki, N, Izumi, M, Hara, N & Nakanishi, Y 2008, 'Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer', Respirology, vol. 13, no. 1, pp. 103-107. https://doi.org/10.1111/j.1440-1843.2007.01190.x
Takayama, Koichi ; Kawasaki, Masayuki ; Ninomiya, Kiyoshi ; Motohiro, Akira ; Fujita, Masaki ; Watanabe, Kentaro ; Kajiki, Akira ; Iwami, Fumiyuki ; Miyazaki, Naoki ; Izumi, Miiru ; Hara, Nobuyuki ; Nakanishi, Yoichi. / Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. In: Respirology. 2008 ; Vol. 13, No. 1. pp. 103-107.
@article{0f35f8e68ef34ca7baddfd31c2774614,
title = "Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer",
abstract = "Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3{\%}; 95{\%} CI 21.2-43.4{\%}). The median survival time was 8.6 months, and the 1-year survival was 41.5{\%}. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7{\%}) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5{\%}) patients, nausea and vomiting with WHO grade 3 in 4 (6.3{\%}), diarrhoea with WHO grade 4 in 1 (1.6{\%}), and liver dysfunction with WHO grade 4 in 1 (1.6{\%}) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.",
author = "Koichi Takayama and Masayuki Kawasaki and Kiyoshi Ninomiya and Akira Motohiro and Masaki Fujita and Kentaro Watanabe and Akira Kajiki and Fumiyuki Iwami and Naoki Miyazaki and Miiru Izumi and Nobuyuki Hara and Yoichi Nakanishi",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1440-1843.2007.01190.x",
language = "English",
volume = "13",
pages = "103--107",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer

AU - Takayama, Koichi

AU - Kawasaki, Masayuki

AU - Ninomiya, Kiyoshi

AU - Motohiro, Akira

AU - Fujita, Masaki

AU - Watanabe, Kentaro

AU - Kajiki, Akira

AU - Iwami, Fumiyuki

AU - Miyazaki, Naoki

AU - Izumi, Miiru

AU - Hara, Nobuyuki

AU - Nakanishi, Yoichi

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2-43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.

AB - Background and objective: A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen. Methods: The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m2 oral UFT from day 1 to day 14 and 80 mg/m2 cisplatin on day 15. The treatment course was repeated every 3 weeks. Results: Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2-43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity ≥WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient. Conclusions: The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=38049153042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049153042&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2007.01190.x

DO - 10.1111/j.1440-1843.2007.01190.x

M3 - Article

C2 - 18197918

AN - SCOPUS:38049153042

VL - 13

SP - 103

EP - 107

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 1

ER -